This page contains information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.
On this page:
Texas received a very small final distribution of bebtelovimab from the United States Government (USG) to be utilized exclusively for persons who are uninsured or underinsured. See the 9/09/22 DSHS communication to providers for more information.
Bebtelovimab will become available for purchase from the distributor AmerisourceBergen (ABC) during the week of August 15, 2022. See the 8/04/22 DSHS communication to providers for more information.
To enroll as a therapeutics provider, please email therapeutics@dshs.texas.gov or call Provider Support at 833‑832‑7068, option 0.
Click on any of the buttons below to access a list of product-specific resources.
Shelf-life extension information can be found individually in each of the applicable product-specific sections, as well as in the Shelf-Life Extensions section below.
For the latest information on product distribution across the state, see the Texas COVID-19 Product Availability section.
Bamlanivimab + Etesevimab (Lilly) Casirivimab + Imdevimab (Regeneron) Sotrovimab (GlaxoSmithKline) Bebtelovimab (Lilly)
Evusheld: tixagevimab + cilgavimab (AstraZeneca)
Lagevrio (molnupiravir) (Merck) Paxlovid: nirmatrelvir + ritonavir (Pfizer)
▲ Top
This page is being updated as new information becomes available.